{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:56:40Z","timestamp":1794887800775,"version":"4.9.1"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["26893188"],"award-info":[{"award-number":["26893188"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.cyto.2016.08.014","type":"journal-article","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T22:52:12Z","timestamp":1472511132000},"page":"56-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":308,"special_numbering":"C","title":["Molecular mechanisms of action of anti-TNF-\u03b1 agents \u2013 Comparison among therapeutic TNF-\u03b1 antagonists"],"prefix":"10.1016","volume":"101","author":[{"given":"Hiroki","family":"Mitoma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyasu","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cyto.2016.08.014_b0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.cyto.2016.08.014_b0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J. Pathol."},{"issue":"2","key":"10.1016\/j.cyto.2016.08.014_b0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0092-8674(90)90158-B","article-title":"A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact","volume":"63","author":"Perez","year":"1990","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.cyto.2016.08.014_b0020","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology (Oxford, England)"},{"issue":"10","key":"10.1016\/j.cyto.2016.08.014_b0025","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1002\/eji.1830271018","article-title":"A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55\/p75 TNF receptor signaling","volume":"27","author":"Alexopoulou","year":"1997","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2016.08.014_b0030","first-page":"86","article-title":"Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice","volume":"46","author":"Georgopoulos","year":"1996","journal-title":"J. Inflamm."},{"issue":"5","key":"10.1016\/j.cyto.2016.08.014_b0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cytogfr.2004.03.011","article-title":"Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system","volume":"15","author":"Eissner","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"issue":"12","key":"10.1016\/j.cyto.2016.08.014_b0040","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.4049\/jimmunol.164.12.6193","article-title":"Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages","volume":"164","author":"Eissner","year":"2000","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"1","key":"10.1016\/j.cyto.2016.08.014_b0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4049\/jimmunol.166.1.130","article-title":"Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells","volume":"166","author":"Harashima","year":"2001","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"6","key":"10.1016\/j.cyto.2016.08.014_b0050","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.4049\/jimmunol.179.6.4239","article-title":"Interaction between transmembrane TNF and TNFR1\/2 mediates the activation of monocytes by contact with T cells","volume":"179","author":"Rossol","year":"2007","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"4","key":"10.1016\/j.cyto.2016.08.014_b0055","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2567.2005.02190.x","article-title":"Reverse signalling of membrane-integrated tumour necrosis factor differentially regulates alloresponses of CD4+ and CD8+ T cells against human microvascular endothelial cells","volume":"115","author":"Vudattu","year":"2005","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.cyto.2016.08.014_b0060","first-page":"885","article-title":"Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNF-alpha-mediated \u2019reverse signaling\u2019","volume":"18","author":"Xin","year":"2006","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"10.1016\/j.cyto.2016.08.014_b0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejcb.2008.09.001","article-title":"Influence of reverse signaling via membrane TNF-alpha on cytotoxicity of NK92 cells","volume":"88","author":"Yu","year":"2009","journal-title":"Eur. J. Cell Biol."},{"issue":"1 Suppl","key":"10.1016\/j.cyto.2016.08.014_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/03946320140270S101","article-title":"The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases","volume":"27","author":"Blandizzi","year":"2014","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"1","key":"10.1016\/j.cyto.2016.08.014_b0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Behcet\u2019s disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.cyto.2016.08.014_b0080","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","article-title":"TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants \u2013 past, present and future","volume":"25","author":"Sedger","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"issue":"8","key":"10.1016\/j.cyto.2016.08.014_b0085","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of action of Anti-TNF therapy in inflammatory bowel disease","volume":"10","author":"Levin","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"5","key":"10.1016\/j.cyto.2016.08.014_b0090","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s12325-013-0026-3","article-title":"Efficacy and safety of certolizumab pegol for Crohn\u2019s disease: a systematic review and meta-analysis","volume":"30","author":"Da","year":"2013","journal-title":"Adv. Therapy"},{"issue":"3","key":"10.1016\/j.cyto.2016.08.014_b0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn\u2019s disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"New Engl. J. Med."},{"issue":"8","key":"10.1016\/j.cyto.2016.08.014_b0100","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cgh.2011.04.031","article-title":"Certolizumab pegol for active Crohn\u2019s disease: a placebo-controlled, randomized trial","volume":"9","author":"Sandborn","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol.: Official Clin. Practice J. Am. Gastroenterol. Assoc."},{"issue":"7","key":"10.1016\/j.cyto.2016.08.014_b0105","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.cgh.2006.04.022","article-title":"Onercept for moderate-to-severe Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"4","author":"Rutgeerts","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol.: Official Clin. Practice J. Am. Gastroenterol. Assoc."},{"issue":"10","key":"10.1016\/j.cyto.2016.08.014_b0110","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and tuberculosis risks","volume":"8","author":"Wallis","year":"2008","journal-title":"Lancet. Infect. Dis"},{"issue":"5 Suppl1","key":"10.1016\/j.cyto.2016.08.014_b0115","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.semarthrit.2005.01.009","article-title":"Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab","volume":"34","author":"Wallis","year":"2005","journal-title":"Semin. Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.cyto.2016.08.014_b0120","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/gutjnl-2011-300384","article-title":"MTNF reverse signalling induced by TNFalpha antagonists involves a GDF-1 dependent pathway: implications for Crohn\u2019s disease","volume":"62","author":"Derer","year":"2013","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cyto.2016.08.014_b0125","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","article-title":"Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor","volume":"131","author":"Kaymakcalan","year":"2009","journal-title":"Clin. Immunol. (Orlando, Fla.)"},{"issue":"2","key":"10.1016\/j.cyto.2016.08.014_b0130","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/j.gastro.2004.11.060","article-title":"Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha","volume":"128","author":"Mitoma","year":"2005","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cyto.2016.08.014_b0135","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/art.23447","article-title":"Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab","volume":"58","author":"Mitoma","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.cyto.2016.08.014_b0140","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"issue":"6","key":"10.1016\/j.cyto.2016.08.014_b0145","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/00054725-200411000-00015","article-title":"Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn\u2019s disease","volume":"10","author":"Ringheanu","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.cyto.2016.08.014_b0150","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.cyto.2016.08.014_b0155","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4161\/mabs.12304","article-title":"Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha","volume":"2","author":"Shealy","year":"2010","journal-title":"mAbs"},{"issue":"6","key":"10.1016\/j.cyto.2016.08.014_b0160","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/MIB.0b013e318280b169","article-title":"The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor alpha","volume":"19","author":"Ueda","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"issue":"7","key":"10.1016\/j.cyto.2016.08.014_b0165","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn\u2019s disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cyto.2016.08.014_b0170","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2010.10.008","article-title":"Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner","volume":"140","author":"Vos","year":"2011","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.cyto.2016.08.014_b0175","doi-asserted-by":"crossref","first-page":"e43361","DOI":"10.1371\/journal.pone.0043361","article-title":"Fc gamma receptor CD64 modulates the inhibitory activity of infliximab","volume":"7","author":"Wojtal","year":"2012","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.cyto.2016.08.014_b0180","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.4049\/jimmunol.0903296","article-title":"Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR","volume":"184","author":"Suzuki","year":"2010","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"6","key":"10.1016\/j.cyto.2016.08.014_b0185","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1053\/j.gastro.2015.07.002","article-title":"Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease","volume":"149","author":"Biancheri","year":"2015","journal-title":"Gastroenterology"},{"issue":"1\u20132","key":"10.1016\/j.cyto.2016.08.014_b0190","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jim.2009.06.009","article-title":"Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis","volume":"348","author":"Palframan","year":"2009","journal-title":"J. Immunol. Methods"},{"issue":"5","key":"10.1016\/j.cyto.2016.08.014_b0195","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jlb.58.5.495","article-title":"Alveolar macrophages as a cell source of cytokine hyperproduction in HIV-related interstitial lung disease","volume":"58","author":"Agostini","year":"1995","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.cyto.2016.08.014_b0200","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1165\/ajrcmb.22.1.3728","article-title":"Increased expression of functionally active membrane-associated tumor necrosis factor in acute respiratory distress syndrome","volume":"22","author":"Armstrong","year":"2000","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"11","key":"10.1016\/j.cyto.2016.08.014_b0205","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3588::AID-IMMU3588>3.0.CO;2-O","article-title":"Human NK cells constitutively express membrane TNF-alpha (mTNFalpha) and present mTNFalpha-dependent cytotoxic activity","volume":"29","author":"Caron","year":"1999","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2016.08.014_b0210","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0008-8749(91)90066-K","article-title":"Cytolytic activities of activated macrophages versus paraformaldehyde-fixed macrophages; soluble versus membrane-associated TNF","volume":"137","author":"Fishman","year":"1991","journal-title":"Cell. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2016.08.014_b0215","first-page":"875","article-title":"Increased expression of membrane TNF-alpha on activated peripheral CD8+ T cells in systemic lupus erythematosus","volume":"17","author":"Horiuchi","year":"2006","journal-title":"Int. J. Mol. Med."},{"issue":"6","key":"10.1016\/j.cyto.2016.08.014_b0220","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.4049\/jimmunol.175.6.4076","article-title":"Kupffer cell-expressed membrane-bound TNF mediates melphalan hepatotoxicity via activation of both TNF receptors","volume":"175","author":"Kresse","year":"2005","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"1","key":"10.1016\/j.cyto.2016.08.014_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0008-8749(89)90143-3","article-title":"Cell surface tumor necrosis factor (TNF) accounts for monocyte- and lymphocyte-mediated killing of TNF-resistant target cells","volume":"122","author":"Peck","year":"1989","journal-title":"Cell. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2016.08.014_b0230","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/jlb.51.3.296","article-title":"Soluble TNF and membrane TNF expressed on CD4+ T lymphocytes differ in their ability to activate macrophage antileishmanial defense","volume":"51","author":"Birkland","year":"1992","journal-title":"J. Leukoc. Biol."},{"issue":"6618","key":"10.1016\/j.cyto.2016.08.014_b0235","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/385729a0","article-title":"A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells","volume":"385","author":"Black","year":"1997","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cyto.2016.08.014_b0240","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1084\/jem.185.1.81","article-title":"Membrane tumor necrosis factor (TNF) induced cooperative signaling of TNFR60 and TNFR80 favors induction of cell death rather than virus production in HIV-infected T cells","volume":"185","author":"Lazdins","year":"1997","journal-title":"J. Exp. Med."},{"issue":"25","key":"10.1016\/j.cyto.2016.08.014_b0245","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1021\/bi952182t","article-title":"Human pro-tumor necrosis factor is a homotrimer","volume":"35","author":"Tang","year":"1996","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.cyto.2016.08.014_b0250","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80kDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.cyto.2016.08.014_b0255","first-page":"411","article-title":"Receptor-like properties of the 26kDa transmembrane form of TNF","volume":"12","author":"Domonkos","year":"2001","journal-title":"Eur. Cytokine Netw."},{"issue":"8","key":"10.1016\/j.cyto.2016.08.014_b0260","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/ncb1450","article-title":"A gamma-secretase-like intramembrane cleavage of TNFalpha by the GxGD aspartyl protease SPPL2b","volume":"8","author":"Fluhrer","year":"2006","journal-title":"Nat. Cell Biol."},{"issue":"8","key":"10.1016\/j.cyto.2016.08.014_b0265","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ncb1440","article-title":"SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production","volume":"8","author":"Friedmann","year":"2006","journal-title":"Nat. Cell Biol."},{"issue":"10","key":"10.1016\/j.cyto.2016.08.014_b0270","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0962-8924(00)89088-1","article-title":"Two tumour necrosis factor receptors: structure and function","volume":"5","author":"Vandenabeele","year":"1995","journal-title":"Trends Cell Biol."},{"issue":"5475","key":"10.1016\/j.cyto.2016.08.014_b0275","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1126\/science.288.5475.2351","article-title":"A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling","volume":"288","author":"Chan","year":"2000","journal-title":"Science (New York, N.Y.)"},{"issue":"4","key":"10.1016\/j.cyto.2016.08.014_b0280","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/sj.bjp.0704549","article-title":"TNF ligands and receptors\u2013a matter of life and death","volume":"135","author":"MacEwan","year":"2002","journal-title":"Br. J. Pharmacol."},{"issue":"16","key":"10.1016\/j.cyto.2016.08.014_b0285","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.2174\/0929867043364694","article-title":"Function and regulation of tumor necrosis factor receptor type 2","volume":"11","author":"Carpentier","year":"2004","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.cyto.2016.08.014_b0290","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/clin.1996.4291","article-title":"Membrane tumor necrosis factor-alpha (TNF-alpha) expressed on HTLV-I-infected T cells mediates a costimulatory signal for B cell activation\u2013characterization of membrane TNF-alpha","volume":"82","author":"Higuchi","year":"1997","journal-title":"Clin. Immunol. Immunopathol."},{"issue":"8","key":"10.1016\/j.cyto.2016.08.014_b0295","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/emboj\/18.8.2119","article-title":"A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in \u2019reverse signalling\u2019","volume":"18","author":"Watts","year":"1999","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.cyto.2016.08.014_b0300","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.jidsymp.5650034","article-title":"Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs","volume":"12","author":"Kohno","year":"2007","journal-title":"J. Investig. Dermatol. Symp. Proc.\/The Society for Investigative Dermatology, Inc. [and] European Society for Dermatological Research"},{"issue":"2","key":"10.1016\/j.cyto.2016.08.014_b0305","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cyto.2008.11.008","article-title":"Differences in binding and effector functions between classes of TNF antagonists","volume":"45","author":"Arora","year":"2009","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.cyto.2016.08.014_b0310","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1053\/j.gastro.2004.01.036","article-title":"Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha","volume":"126","author":"Mitoma","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cyto.2016.08.014_b0315","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cytogfr.2014.02.001","article-title":"Lymphotoxin and TNF: how it all began-a tribute to the travelers","volume":"25","author":"Ruddle","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2","key":"10.1016\/j.cyto.2016.08.014_b0320","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cyto.2010.10.010","article-title":"Lymphotoxin alpha stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts","volume":"53","author":"Calmon-Hamaty","year":"2011","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.cyto.2016.08.014_b0325","doi-asserted-by":"crossref","first-page":"R202","DOI":"10.1186\/ar4393","article-title":"Evidence that TNF-beta (lymphotoxin alpha) can activate the inflammatory environment in human chondrocytes","volume":"15","author":"Buhrmann","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.cyto.2016.08.014_b0330","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/03009742.2013.834964","article-title":"Etanercept decreases synovial expression of tumour necrosis factor-alpha and lymphotoxin-alpha in rheumatoid arthritis","volume":"43","author":"Neregard","year":"2014","journal-title":"Scand. J. Rheumatol."},{"issue":"5","key":"10.1016\/j.cyto.2016.08.014_b0335","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s13075-014-0467-3","article-title":"Efficacy and safety of pateclizumab (anti-lymphotoxin-alpha) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)","volume":"16","author":"Kennedy","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cyto.2016.08.014_b0340","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1196\/annals.1326.029","article-title":"Role of lymphotoxins in the development of Peyer\u2019s patches and mesenteric lymph nodes: relevance to intestinal inflammation and treatment","volume":"1072","author":"Spahn","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"28","key":"10.1016\/j.cyto.2016.08.014_b0345","doi-asserted-by":"crossref","first-page":"18520","DOI":"10.1016\/S0021-9258(18)55092-4","article-title":"Localization of the human complement component C3 binding site on the IgG heavy chain","volume":"266","author":"Shohet","year":"1991","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.cyto.2016.08.014_b0350","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1016\/S0021-9258(18)53400-1","article-title":"Identification of a major binding site for complement C3 on the IgG1 heavy chain","volume":"268","author":"Shohet","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"41","key":"10.1016\/j.cyto.2016.08.014_b0355","doi-asserted-by":"crossref","first-page":"38217","DOI":"10.1074\/jbc.M104870200","article-title":"Serine 132 is the C3 covalent attachment point on the CH1 domain of human IgG1","volume":"276","author":"Vidarte","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"13\u201314","key":"10.1016\/j.cyto.2016.08.014_b0360","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0161-5890(99)00105-4","article-title":"The covalent interaction of C3 with IgG immune complexes","volume":"36","author":"Vivanco","year":"1999","journal-title":"Mol. Immunol."},{"issue":"46","key":"10.1016\/j.cyto.2016.08.014_b0365","doi-asserted-by":"crossref","first-page":"28997","DOI":"10.1016\/S0021-9258(19)62004-1","article-title":"Covalent attachment of human complement C3 to IgG. Identification of the amino acid residue involved in ester linkage formation","volume":"269","author":"Sahu","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.cyto.2016.08.014_b0370","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.imlet.2006.05.009","article-title":"Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences","volume":"106","author":"Siberil","year":"2006","journal-title":"Immunol. Lett."},{"issue":"2","key":"10.1016\/j.cyto.2016.08.014_b0375","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.50.2.206","article-title":"Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn\u2019s disease","volume":"50","author":"ten Hove","year":"2002","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cyto.2016.08.014_b0380","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/gut.2006.105379","article-title":"Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn\u2019s disease","volume":"56","author":"Van den Brande","year":"2007","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cyto.2016.08.014_b0385","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2133.2007.07945.x","article-title":"Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function","volume":"157","author":"Bedini","year":"2007","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.cyto.2016.08.014_b0390","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/MIB.0b013e318280292b","article-title":"Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy","volume":"19","author":"Caprioli","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"issue":"9","key":"10.1016\/j.cyto.2016.08.014_b0395","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin. Infect. Dis.: Official Publ. Infect. Dis. Soc. Am."},{"issue":"5","key":"10.1016\/j.cyto.2016.08.014_b0400","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI38482","article-title":"Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans","volume":"119","author":"Bruns","year":"2009","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.cyto.2016.08.014_b0405","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1053\/j.gastro.2011.08.032","article-title":"Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages","volume":"141","author":"Atreya","year":"2011","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cyto.2016.08.014_b0410","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.4049\/jimmunol.1000560","article-title":"Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells","volume":"185","author":"Kleijwegt","year":"2010","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"7","key":"10.1016\/j.cyto.2016.08.014_b0415","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.4049\/jimmunol.0902070","article-title":"TNF activates a NF-\u03baB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function","volume":"184","author":"Nagar","year":"2010","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"1","key":"10.1016\/j.cyto.2016.08.014_b0420","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ibd.21308","article-title":"Therapy with anti-TNFalpha antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases","volume":"17","author":"Boschetti","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cyto.2016.08.014_b0425","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1196\/annals.1361.095","article-title":"Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab","volume":"1051","author":"Toubi","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.cyto.2016.08.014_b0430","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood-2005-11-4567","article-title":"TNF downmodulates the function of human CD4+CD25hi T-regulatory cells","volume":"108","author":"Valencia","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cyto.2016.08.014_b0435","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cellimm.2012.09.001","article-title":"Anti-TNF-alpha therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis","volume":"279","author":"Huang","year":"2012","journal-title":"Cell. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2016.08.014_b0440","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1084\/jem.20061531","article-title":"Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta","volume":"204","author":"Nadkarni","year":"2007","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.cyto.2016.08.014_b0445","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nm.3085","article-title":"Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis","volume":"19","author":"Nie","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.cyto.2016.08.014_b0450","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/nm.4019","article-title":"Suppressive activity of human regulatory T cells is maintained in the presence of TNF","volume":"22","author":"Zaragoza","year":"2016","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.cyto.2016.08.014_b0455","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.4049\/jimmunol.1202659","article-title":"TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment","volume":"190","author":"Chen","year":"2013","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"6","key":"10.1016\/j.cyto.2016.08.014_b0460","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/carcin\/bgt038","article-title":"Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis","volume":"34","author":"Chopra","year":"2013","journal-title":"Carcinogenesis"},{"issue":"12","key":"10.1016\/j.cyto.2016.08.014_b0465","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1172\/JCI42945","article-title":"Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs","volume":"120","author":"Grinberg-Bleyer","year":"2010","journal-title":"J. Clin. Investig."},{"issue":"10","key":"10.1016\/j.cyto.2016.08.014_b0470","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/art.38755","article-title":"Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis","volume":"66","author":"McCann","year":"2014","journal-title":"Arthritis Rheumatol. (Hoboken, N.J.)"},{"issue":"7","key":"10.1016\/j.cyto.2016.08.014_b0475","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1084\/jem.20151255","article-title":"Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis","volume":"213","author":"Nguyen","year":"2016","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.cyto.2016.08.014_b0480","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ibd.21818","article-title":"Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro","volume":"18","author":"Vos","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cyto.2016.08.014_b0485","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coi.2016.03.005","article-title":"Harnessing Fc receptor biology in the design of therapeutic antibodies","volume":"40","author":"Sondermann","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2016.08.014_b0490","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2036.2004.01871.x","article-title":"Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn\u2019s disease","volume":"19","author":"Louis","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.cyto.2016.08.014_b0495","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/01.fpc.0000230421.12844.fd","article-title":"Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn\u2019s disease: a subanalysis of the ACCENT I study","volume":"16","author":"Louis","year":"2006","journal-title":"Pharmacogenet. Genomics"},{"issue":"4","key":"10.1016\/j.cyto.2016.08.014_b0500","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00251-013-0679-8","article-title":"FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn\u2019s disease through affecting the ADCC activity","volume":"65","author":"Moroi","year":"2013","journal-title":"Immunogenetics"},{"issue":"5","key":"10.1016\/j.cyto.2016.08.014_b0505","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40262-014-0225-3","article-title":"Assessment of the influence of inflammation and FCGR3A genotype on infliximab pharmacokinetics and time to relapse in patients with Crohn\u2019s disease","volume":"54","author":"Ternant","year":"2015","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.cyto.2016.08.014_b0510","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pep.2009.12.004","article-title":"Expression of soluble and functional human neonatal Fc receptor in Pichia pastoris","volume":"71","author":"Lee","year":"2010","journal-title":"Protein Expr. Purif."},{"issue":"3","key":"10.1016\/j.cyto.2016.08.014_b0515","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol.: Official Clin. Practice J. Am. Gastroenterol. Assoc."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466616304689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466616304689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T20:02:27Z","timestamp":1657224147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466616304689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":103,"alternative-id":["S1043466616304689"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2016.08.014","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular mechanisms of action of anti-TNF-\u03b1 agents \u2013 Comparison among therapeutic TNF-\u03b1 antagonists","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2016.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}